Contribute Try STAT+ Today

“CRISPR babies” scientist He Jiankui tried to publish a paper describing additional experiments that made heritable changes in the DNA of human embryos, much like those that led to the birth of the world’s first genome-edited humans. But the paper was rejected by an international journal after outside scientists raised concerns about both its ethics and its scientific validity, STAT has learned.

The rejected paper did not report starting a pregnancy with the edited embryos, and “there is no plan” to do so, said Ryan Ferrell, He’s public relations consultant. It is nevertheless one of a tiny handful of experiments editing normal human embryos: A Chinese lab did it in 2017, a U.S. lab followed a few months later, and another Chinese lab did it this summer. And it would make He’s one of only two labs in the world known to have edited human embryos to alter genes for more than one disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.